Opioid Induced Constipation Industry

2021-2027 Global and Regional Opioid-Induced Constipation Industry Status and Prospects Professional Market Research Report Standard Version


Date: Aug-2021 | Id: MACRC-72284 | Geographical Scope: Global | Publisher: Mnemonics Research

The global Opioid-Induced Constipation market was valued at 219.65 Million USD in 2020 and will grow with a CAGR of 5% from 2020 to 2027, based on Mnemonics Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation.Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%. North America is the largest Sales place, with a Sales market share nearly 56.48% in 2017. Following North America, Europe is the second largest Sales place with the Sales market share of 20.49%.  
By Market Verdors:
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi

By Types:
Methylnaltrexone Bromide
Lubiprostone
Naloxegol

By Applications:
Hospital
Pharmacy

Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and <b>Drivers:</b> Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global  market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.

Chapter 1 Industry Overview 1.1 Definition 1.2 Assumptions 1.3 Research Scope 1.4 Market Analysis by Regions 1.4.1 North America Market States and Outlook (2022-2027) 1.4.2 East Asia Market States and Outlook (2022-2027) 1.4.3 Europe Market States and Outlook (2022-2027) 1.4.4 South Asia Market States and Outlook (2022-2027) 1.4.5 Southeast Asia Market States and Outlook (2022-2027) 1.4.6 Middle East Market States and Outlook (2022-2027) 1.4.7 Africa Market States and Outlook (2022-2027) 1.4.8 Oceania Market States and Outlook (2022-2027) 1.4.9 South America Market States and Outlook (2022-2027) 1.5 Global Opioid-Induced Constipation Market Size Analysis from 2022 to 2027 1.5.1 Global Opioid-Induced Constipation Market Size Analysis from 2022 to 2027 by Consumption Volume 1.5.2 Global Opioid-Induced Constipation Market Size Analysis from 2022 to 2027 by Value 1.5.3 Global Opioid-Induced Constipation Price Trends Analysis from 2022 to 2027 1.6 COVID-19 Outbreak: Opioid-Induced Constipation Industry Impact Chapter 2 Global Opioid-Induced Constipation Competition by Types, Applications, and Top Regions and Countries 2.1 Global Opioid-Induced Constipation (Volume and Value) by Type 2.1.1 Global Opioid-Induced Constipation Consumption and Market Share by Type (2016-2021) 2.1.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2016-2021) 2.2 Global Opioid-Induced Constipation (Volume and Value) by Application 2.2.1 Global Opioid-Induced Constipation Consumption and Market Share by Application (2016-2021) 2.2.2 Global Opioid-Induced Constipation Revenue and Market Share by Application (2016-2021) 2.3 Global Opioid-Induced Constipation (Volume and Value) by Regions 2.3.1 Global Opioid-Induced Constipation Consumption and Market Share by Regions (2016-2021) 2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Regions (2016-2021) Chapter 3 Production Market Analysis 3.1 Global Production Market Analysis 3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis 3.1.2 2016-2021 Major Manufacturers Performance and Market Share 3.2 Regional Production Market Analysis 3.2.1 2016-2021 Regional Market Performance and Market Share 3.2.2 North America Market 3.2.3 East Asia Market 3.2.4 Europe Market 3.2.5 South Asia Market 3.2.6 Southeast Asia Market 3.2.7 Middle East Market 3.2.8 Africa Market 3.2.9 Oceania Market 3.2.10 South America Market 3.2.11 Rest of the World Market Chapter 4 Global Opioid-Induced Constipation Sales, Consumption, Export, Import by Regions (2016-2021) 4.1 Global Opioid-Induced Constipation Consumption by Regions (2016-2021) 4.2 North America Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021) 4.3 East Asia Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021) 4.4 Europe Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021) 4.5 South Asia Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021) 4.6 Southeast Asia Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021) 4.7 Middle East Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021) 4.8 Africa Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021) 4.9 Oceania Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021) 4.10 South America Opioid-Induced Constipation Sales, Consumption, Export, Import (2016-2021) Chapter 5 North America Opioid-Induced Constipation Market Analysis 5.1 North America Opioid-Induced Constipation Consumption and Value Analysis 5.1.1 North America Opioid-Induced Constipation Market Under COVID-19 5.2 North America Opioid-Induced Constipation Consumption Volume by Types 5.3 North America Opioid-Induced Constipation Consumption Structure by Application 5.4 North America Opioid-Induced Constipation Consumption by Top Countries 5.4.1 United States Opioid-Induced Constipation Consumption Volume from 2016 to 2021 5.4.2 Canada Opioid-Induced Constipation Consumption Volume from 2016 to 2021 5.4.3 Mexico Opioid-Induced Constipation Consumption Volume from 2016 to 2021 Chapter 6 East Asia Opioid-Induced Constipation Market Analysis 6.1 East Asia Opioid-Induced Constipation Consumption and Value Analysis 6.1.1 East Asia Opioid-Induced Constipation Market Under COVID-19 6.2 East Asia Opioid-Induced Constipation Consumption Volume by Types 6.3 East Asia Opioid-Induced Constipation Consumption Structure by Application 6.4 East Asia Opioid-Induced Constipation Consumption by Top Countries 6.4.1 China Opioid-Induced Constipation Consumption Volume from 2016 to 2021 6.4.2 Japan Opioid-Induced Constipation Consumption Volume from 2016 to 2021 6.4.3 South Korea Opioid-Induced Constipation Consumption Volume from 2016 to 2021 Chapter 7 Europe Opioid-Induced Constipation Market Analysis 7.1 Europe Opioid-Induced Constipation Consumption and Value Analysis 7.1.1 Europe Opioid-Induced Constipation Market Under COVID-19 7.2 Europe Opioid-Induced Constipation Consumption Volume by Types 7.3 Europe Opioid-Induced Constipation Consumption Structure by Application 7.4 Europe Opioid-Induced Constipation Consumption by Top Countries 7.4.1 Germany Opioid-Induced Constipation Consumption Volume from 2016 to 2021 7.4.2 UK Opioid-Induced Constipation Consumption Volume from 2016 to 2021 7.4.3 France Opioid-Induced Constipation Consumption Volume from 2016 to 2021 7.4.4 Italy Opioid-Induced Constipation Consumption Volume from 2016 to 2021 7.4.5 Russia Opioid-Induced Constipation Consumption Volume from 2016 to 2021 7.4.6 Spain Opioid-Induced Constipation Consumption Volume from 2016 to 2021 7.4.7 Netherlands Opioid-Induced Constipation Consumption Volume from 2016 to 2021 7.4.8 Switzerland Opioid-Induced Constipation Consumption Volume from 2016 to 2021 7.4.9 Poland Opioid-Induced Constipation Consumption Volume from 2016 to 2021 Chapter 8 South Asia Opioid-Induced Constipation Market Analysis 8.1 South Asia Opioid-Induced Constipation Consumption and Value Analysis 8.1.1 South Asia Opioid-Induced Constipation Market Under COVID-19 8.2 South Asia Opioid-Induced Constipation Consumption Volume by Types 8.3 South Asia Opioid-Induced Constipation Consumption Structure by Application 8.4 South Asia Opioid-Induced Constipation Consumption by Top Countries 8.4.1 India Opioid-Induced Constipation Consumption Volume from 2016 to 2021 8.4.2 Pakistan Opioid-Induced Constipation Consumption Volume from 2016 to 2021 8.4.3 Bangladesh Opioid-Induced Constipation Consumption Volume from 2016 to 2021 Chapter 9 Southeast Asia Opioid-Induced Constipation Market Analysis 9.1 Southeast Asia Opioid-Induced Constipation Consumption and Value Analysis 9.1.1 Southeast Asia Opioid-Induced Constipation Market Under COVID-19 9.2 Southeast Asia Opioid-Induced Constipation Consumption Volume by Types 9.3 Southeast Asia Opioid-Induced Constipation Consumption Structure by Application 9.4 Southeast Asia Opioid-Induced Constipation Consumption by Top Countries 9.4.1 Indonesia Opioid-Induced Constipation Consumption Volume from 2016 to 2021 9.4.2 Thailand Opioid-Induced Constipation Consumption Volume from 2016 to 2021 9.4.3 Singapore Opioid-Induced Constipation Consumption Volume from 2016 to 2021 9.4.4 Malaysia Opioid-Induced Constipation Consumption Volume from 2016 to 2021 9.4.5 Philippines Opioid-Induced Constipation Consumption Volume from 2016 to 2021 9.4.6 Vietnam Opioid-Induced Constipation Consumption Volume from 2016 to 2021 9.4.7 Myanmar Opioid-Induced Constipation Consumption Volume from 2016 to 2021 Chapter 10 Middle East Opioid-Induced Constipation Market Analysis 10.1 Middle East Opioid-Induced Constipation Consumption and Value Analysis 10.1.1 Middle East Opioid-Induced Constipation Market Under COVID-19 10.2 Middle East Opioid-Induced Constipation Consumption Volume by Types 10.3 Middle East Opioid-Induced Constipation Consumption Structure by Application 10.4 Middle East Opioid-Induced Constipation Consumption by Top Countries 10.4.1 Turkey Opioid-Induced Constipation Consumption Volume from 2016 to 2021 10.4.2 Saudi Arabia Opioid-Induced Constipation Consumption Volume from 2016 to 2021 10.4.3 Iran Opioid-Induced Constipation Consumption Volume from 2016 to 2021 10.4.4 United Arab Emirates Opioid-Induced Constipation Consumption Volume from 2016 to 2021 10.4.5 Israel Opioid-Induced Constipation Consumption Volume from 2016 to 2021 10.4.6 Iraq Opioid-Induced Constipation Consumption Volume from 2016 to 2021 10.4.7 Qatar Opioid-Induced Constipation Consumption Volume from 2016 to 2021 10.4.8 Kuwait Opioid-Induced Constipation Consumption Volume from 2016 to 2021 10.4.9 Oman Opioid-Induced Constipation Consumption Volume from 2016 to 2021 Chapter 11 Africa Opioid-Induced Constipation Market Analysis 11.1 Africa Opioid-Induced Constipation Consumption and Value Analysis 11.1.1 Africa Opioid-Induced Constipation Market Under COVID-19 11.2 Africa Opioid-Induced Constipation Consumption Volume by Types 11.3 Africa Opioid-Induced Constipation Consumption Structure by Application 11.4 Africa Opioid-Induced Constipation Consumption by Top Countries 11.4.1 Nigeria Opioid-Induced Constipation Consumption Volume from 2016 to 2021 11.4.2 South Africa Opioid-Induced Constipation Consumption Volume from 2016 to 2021 11.4.3 Egypt Opioid-Induced Constipation Consumption Volume from 2016 to 2021 11.4.4 Algeria Opioid-Induced Constipation Consumption Volume from 2016 to 2021 11.4.5 Morocco Opioid-Induced Constipation Consumption Volume from 2016 to 2021 Chapter 12 Oceania Opioid-Induced Constipation Market Analysis 12.1 Oceania Opioid-Induced Constipation Consumption and Value Analysis 12.2 Oceania Opioid-Induced Constipation Consumption Volume by Types 12.3 Oceania Opioid-Induced Constipation Consumption Structure by Application 12.4 Oceania Opioid-Induced Constipation Consumption by Top Countries 12.4.1 Australia Opioid-Induced Constipation Consumption Volume from 2016 to 2021 12.4.2 New Zealand Opioid-Induced Constipation Consumption Volume from 2016 to 2021 Chapter 13 South America Opioid-Induced Constipation Market Analysis 13.1 South America Opioid-Induced Constipation Consumption and Value Analysis 13.1.1 South America Opioid-Induced Constipation Market Under COVID-19 13.2 South America Opioid-Induced Constipation Consumption Volume by Types 13.3 South America Opioid-Induced Constipation Consumption Structure by Application 13.4 South America Opioid-Induced Constipation Consumption Volume by Major Countries 13.4.1 Brazil Opioid-Induced Constipation Consumption Volume from 2016 to 2021 13.4.2 Argentina Opioid-Induced Constipation Consumption Volume from 2016 to 2021 13.4.3 Columbia Opioid-Induced Constipation Consumption Volume from 2016 to 2021 13.4.4 Chile Opioid-Induced Constipation Consumption Volume from 2016 to 2021 13.4.5 Venezuela Opioid-Induced Constipation Consumption Volume from 2016 to 2021 13.4.6 Peru Opioid-Induced Constipation Consumption Volume from 2016 to 2021 13.4.7 Puerto Rico Opioid-Induced Constipation Consumption Volume from 2016 to 2021 13.4.8 Ecuador Opioid-Induced Constipation Consumption Volume from 2016 to 2021 Chapter 14 Company Profiles and Key Figures in Opioid-Induced Constipation Business 14.1 Takeda Pharmaceuticals 14.1.1 Takeda Pharmaceuticals Company Profile 14.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Specification 14.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.2 Bayer 14.2.1 Bayer Company Profile 14.2.2 Bayer Opioid-Induced Constipation Product Specification 14.2.3 Bayer Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.3 Sanofi 14.3.1 Sanofi Company Profile 14.3.2 Sanofi Opioid-Induced Constipation Product Specification 14.3.3 Sanofi Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.4 Mallinckrodt 14.4.1 Mallinckrodt Company Profile 14.4.2 Mallinckrodt Opioid-Induced Constipation Product Specification 14.4.3 Mallinckrodt Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.5 Salix (Bausch Health) 14.5.1 Salix (Bausch Health) Company Profile 14.5.2 Salix (Bausch Health) Opioid-Induced Constipation Product Specification 14.5.3 Salix (Bausch Health) Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.6 AstraZeneca 14.6.1 AstraZeneca Company Profile 14.6.2 AstraZeneca Opioid-Induced Constipation Product Specification 14.6.3 AstraZeneca Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.7 Progenics Pharmaceuticals 14.7.1 Progenics Pharmaceuticals Company Profile 14.7.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Specification 14.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.8 Purdue Pharm 14.8.1 Purdue Pharm Company Profile 14.8.2 Purdue Pharm Opioid-Induced Constipation Product Specification 14.8.3 Purdue Pharm Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.9 Nektar Therapeutics 14.9.1 Nektar Therapeutics Company Profile 14.9.2 Nektar Therapeutics Opioid-Induced Constipation Product Specification 14.9.3 Nektar Therapeutics Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.10 Daiichi Sankyo 14.10.1 Daiichi Sankyo Company Profile 14.10.2 Daiichi Sankyo Opioid-Induced Constipation Product Specification 14.10.3 Daiichi Sankyo Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.11 Prestige 14.11.1 Prestige Company Profile 14.11.2 Prestige Opioid-Induced Constipation Product Specification 14.11.3 Prestige Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.12 GSK 14.12.1 GSK Company Profile 14.12.2 GSK Opioid-Induced Constipation Product Specification 14.12.3 GSK Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) 14.13 Shionogi 14.13.1 Shionogi Company Profile 14.13.2 Shionogi Opioid-Induced Constipation Product Specification 14.13.3 Shionogi Opioid-Induced Constipation Production Capacity, Revenue, Price and Gross Margin (2016-2021) Chapter 15 Global Opioid-Induced Constipation Market Forecast (2022-2027) 15.1 Global Opioid-Induced Constipation Consumption Volume, Revenue and Price Forecast (2022-2027) 15.1.1 Global Opioid-Induced Constipation Consumption Volume and Growth Rate Forecast (2022-2027) 15.1.2 Global Opioid-Induced Constipation Value and Growth Rate Forecast (2022-2027) 15.2 Global Opioid-Induced Constipation Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027) 15.2.1 Global Opioid-Induced Constipation Consumption Volume and Growth Rate Forecast by Regions (2022-2027) 15.2.2 Global Opioid-Induced Constipation Value and Growth Rate Forecast by Regions (2022-2027) 15.2.3 North America Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.4 East Asia Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.5 Europe Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.6 South Asia Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.7 Southeast Asia Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.8 Middle East Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.9 Africa Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.10 Oceania Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.2.11 South America Opioid-Induced Constipation Consumption Volume, Revenue and Growth Rate Forecast (2022-2027) 15.3 Global Opioid-Induced Constipation Consumption Volume, Revenue and Price Forecast by Type (2022-2027) 15.3.1 Global Opioid-Induced Constipation Consumption Forecast by Type (2022-2027) 15.3.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2022-2027) 15.3.3 Global Opioid-Induced Constipation Price Forecast by Type (2022-2027) 15.4 Global Opioid-Induced Constipation Consumption Volume Forecast by Application (2022-2027) 15.5 Opioid-Induced Constipation Market Forecast Under COVID-19 Chapter 16 Conclusions Research Methodology

Add to Cart

Single User

$ 3300.00

Site License

$ 5250.00

Enterprisewide

$ 7000.00